Maze Therapeutics, Inc.
$25.06
+3.2%Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -8.2).
Valuation inputs: P/E -8.2, earnings yield N/A, momentum +3.2%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -36.9%, ROIC -37.7%).
Profitability stack: net margin 0.0%, ROE -36.9%, ROIC -37.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +10.6%, momentum +3.2%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Maze Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Maze Therapeutics, Inc. Fair Value Envelope
Maze Therapeutics, Inc. Profit Bridge
Profitability Analysis
Maze Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Maze Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Maze Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that MAZE stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 61.60, with estimates ranging from a low of 46.00 to a high of 97.00.
The consensus 1-year price target stands at 61.60, with estimates ranging from a low of 46.00 to a high of 97.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Maze Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $991K and sold $9.45M worth of MAZE shares, resulting in $8.46M of net selling activity.
3 Months
0
0.00
100.8K
3.54M
-3.5M
-$3.54M
3-6 Months
0
0.00
135.0K
5.44M
-5.4M
-$5.44M
6-9 Months
36.0K
990.72K
20.7K
464.03K
+527K
+$527K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Hoppenot Herve
Director
$991K
Top Sellers
Bernstein Harold
Officer: President, R&D & Cmo
$3.36M
Dandekar Atul
Officer: Csbo
$3.32M
Sohn Catherine A.
Director
$1.15M
Coloma Jason V
Director, Officer: Chief Executive Officer
$830K
Scheller Richard H
Director
$464K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $8.46M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
MAZE has not reported any dividend yield values in the available annual periods.
maze Dividend History
Learning Layer
Related Guides
Build conviction on MAZE by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.